Module 2: Identifying Target Complaints and Setting Goals

Treating Late Life Depression ◽

10.1093/med-psych/9780195383706.003.0002 ◽

2009 ◽

pp. 13-28

Author(s):

Larry W. Thompson ◽

Leah Dick-Siskin ◽

David W. Coon ◽

David V. Powers ◽

Dolores Gallagher-Thompson

Keyword(s):

Rating Scales ◽

Late Life ◽

Late Life Depression ◽

Target Complaints

This chapter discusses identification of target complaints and setting goals in CBT for late-life depression, including steps to identify and prioritize target complaints, rating scales for measuring changes, translating target complaints into goals, and progress towards goals.

Download Full-text

Soluble cell adhesion molecules in late-life depression

International Psychogeriatrics ◽

10.1017/s1041610206004728 ◽

2007 ◽

Vol 19 (5) ◽

pp. 914-920 ◽

Cited By ~ 14

Author(s):

Alan J. Thomas ◽

Christopher Morris ◽

Sue Davis ◽

Elizabeth Jackson ◽

Richard Harrison ◽

...

Keyword(s):

Cell Adhesion ◽

Major Depression ◽

Adhesion Molecules ◽

Adhesion Molecule ◽

Cell Adhesion Molecules ◽

Rating Scales ◽

Vascular Diseases ◽

Late Life ◽

Depression Severity ◽

Late Life Depression

Background: Late-life depression has been associated with vascular diseases and with increases in circulating cytokines and cell adhesion molecules in the prefrontal cortex. We hypothesized that soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) would be increased in late-life major depression.Methods: Serum levels of sICAM-1 and sVCAM-1 were measured in subjects over 60 with major depression (N = 23), subsyndromal depression (N = 20) and controls (N = 25). Depression severity was assessed using the Montgomery-Åsberg (MDRS) and Geriatric Depression (GDS) rating scales.Results: There was no significant increase in sICAM-1 (p = 0.240) or sVCAM-1 (p = 0.600) in depression nor was there any correlation of either molecule with depression severity. Adjusting for differences in cognitive impairment did not alter these findings. There was also no difference between subjects with an early onset of depression (before 60) and those with late-onset depression.Conclusions: These findings do not provide evidence that previously reported increases in serum cytokines in depression are due to peripheral vascular disease. Although we assessed subjects for vascular diseases it is possible that subtle but important differences between groups may still have been present and may have contributed to our negative findings.Our results suggest central nervous system mechanisms, such as related to HPA axis activation, may be responsible for the enhanced inflammatory response in depression.

Download Full-text

Module 2: Identifying Target Complaints and Setting Goals

Treating Late Life Depression ◽

10.1093/med-psych/9780195383690.003.0005 ◽

2009 ◽

pp. 81-90

Author(s):

Dolores Gallagher-Thompson ◽

Larry W. Thompson

Keyword(s):

Late Life ◽

Home Practice ◽

Late Life Depression ◽

Target Complaints

This chapter describes the second module of CBT for late-life depression, which focuses on the identification of target complaints and setting goals. It includes a review of home practice, before identifying and prioritizing target complaints, translating target complaints into goals, progress towards goals, and home practice exercises.

Download Full-text

Refining Evidence-Based Treatments for Late-Life Depression

GeroPsych ◽

10.1024/1662-9647/a000127 ◽

2015 ◽

Vol 28 (2) ◽

pp. 67-76

Author(s):

Grace C. Niu ◽

Patricia A. Arean

Keyword(s):

Older Adults ◽

Mental Illness ◽

Brain Plasticity ◽

Late Life ◽

Aging Population ◽

The United States ◽

Future Research ◽

Evidence Based ◽

Late Life Depression ◽

Evidence Based Treatments

The recent increase in the aging population, specifically in the United States, has raised concerns regarding treatment for mental illness among older adults. Late-life depression (LLD) is a complex condition that has become widespread among the aging population. Despite the availability of behavioral interventions and psychotherapies, few depressed older adults actually receive treatment. In this paper we review the research on refining treatments for LLD. We first identify evidence-based treatments (EBTs) for LLD and the problems associated with efficacy and dissemination, then review approaches to conceptualizing mental illness, specifically concepts related to brain plasticity and the Research Domain Criteria (RDoc). Finally, we introduce ENGAGE as a streamlined treatment for LLD and discuss implications for future research.

Download Full-text